Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.
Kiyotaka YohTomonori HirashimaHideo SakaTakayasu KurataYuichiro OheToyoaki HidaAnders MellemgaardRemy B VerheijenXiaoling OuGhada F AhmedManabu HayamaKo SugibayashiGeoffrey R OxnardPublished in: Targeted oncology (2021)
Clinicaltrials.gov; NCT02143466; 21 May 2014.